Please login to the form below
Hal Barron
This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK’s CEO Emma Walmsley and R&D chief Hal Barron have led the company’s re-entry into oncology, having overseen a number of new additions to the oncology pipeline.
Latest news
-
GSK seeks EU approval for Trelegy in adult asthma patients
We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available,” said Hal Barron,
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
It’s another example of GSK expanding its oncology pipeline under new R&D chief Hal Barron, which has already seen its portfolio double to 17 clinical-stage projects since he ... Barron has said Zejula is one of three that he expects to drive the
-
FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma
ago. GSK’s new CEO Emma Walmsley (pictured left) and new R&D chief Hal Barron have helmed the company’s re-entry into oncology, having overseen a number of new
-
GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus
GSK can't catch up with immunotherapy leaders, such as Merck &Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, but its R&D chief Hal Barron (pictured right) has still ... Barron has also indicated GSK’s interest in cell and gene therapies, which is
-
GSK takes new-class antibiotic into phase 3 for serious infections
Results are expected in 2021. “We believe this drug has the potential to transform the treatment landscape for patients with [these infections] who currently have limited therapeutic options,” commented Hal Barron
More from news
Approximately 1 fully matching, plus 51 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 3)
Walmsley has impressed with a few high-profile hirings to key positions, including Dr Hal Barron as its new R&D supremo, but it will take a few years to see
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Kevin Sin joins GSK
years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.
-
Levinson resigns from Roche board
He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David
-
Roche CMO joins Google health venture Calico
Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
